Keytru­da keeps ex­pand­ing with an­oth­er pri­or­i­ty re­view; Medicxi-backed eye drop mak­er wins new fund­ing, re­gion­al deal

As Mer­ck con­tin­ues to chop away at a path to ear­li­er lines of can­cer treat­ment for Keytru­da, the FDA is of­fer­ing a hand.

The agency has grant­ed pri­or­i­ty re­view for the PD-1 star as an ad­ju­vant ther­a­py in cer­tain pa­tients with re­nal cell car­ci­no­ma — which, if ap­proved, would mark the lat­est in a streak of la­bel ex­pan­sions.

Specif­i­cal­ly, it would be tar­get­ing pa­tients who have in­ter­me­di­ate-high or high risk of re­cur­rence even af­ter sur­gi­cal re­moval of a kid­ney, or fol­low­ing nephrec­to­my and re­sec­tion of metasta­t­ic le­sions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER